vimarsana.com

Latest Breaking News On - Shawn iadonato - Page 7 : vimarsana.com

Kineta (KA) Reports FY22, Provides Corporate Update

Kineta (KA) Reports FY22, Provides Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Canada
United-states
Shawn-iadonato
Merck-co-inc
Exchange-commission
Drug-administration
John-mullalylifesci-advisors
Facebook
Jacques-bouchyevp-investor-relations-business-development
Linkedin
Society-for-immunotherapy-of-cancer
Merck-sharp-dohme

Kineta to Present at the Oppenheimer 33rd Annual Healthcare Conference

Kineta to Present at the Oppenheimer 33rd Annual Healthcare Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Shawn-iadonato
Exchange-commission
Linkedin
Kineta-inc
Jacques-bouchyevp-investor-relations-business-development
Facebook
Nasdaq
John-mullalylifesci-advisors
Chief-executive-officer
Annual-healthcare-conference
Private-securities-litigation-reform-act
Current-report

Kineta to Present at the Oppenheimer 33rd Annual Healthcare

SEATTLE, March 08, 2023 (GLOBE NEWSWIRE) Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel.

John-mullaly
Jacques-bouchy
Shawn-iadonato
Exchange-commission
Linkedin
Lifesci-advisors
Kineta-inc
Facebook
Investor-relations-business-development
Nasdaq
Chief-executive-officer
Annual-healthcare-conference

Yumanity Therapeutics : January 2023 Developing next-generation immunotherapies that address cancer immune resistance KA (Nasdaq) - Form 8-K

January 2023 Developing next-generation immunotherapies that address cancer immune resistance KA Disclaimers and other information Cautionary. | January 5, 2023

Michigan
United-states
Keith-baker
Cetuximab
Craig-philips
Thierry-guillaudeux
Jacques-bouchy-pauline-kenny
Shawn-iadonato
H-single-agent-tumor-product-development
Ch-association
Kineta-inc
Kineta-operating-inc

Kineta Completes Reverse Merger with Yumanity Therapeutics

19.12.2022 - Shares of Kineta to commence trading on Nasdaq under new ticker symbol “KA” on December 19, 2022SEATTLE, Dec. 19, 2022 (GLOBE NEWSWIRE) - Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing . Seite 1

Shawn-iadonato
Kineta-inc
Yumanity-therapeutics-inc
Nasdaq
Yumanity-therapeutics
Nasdaq-capital-market
Investigational-new-drug
Chief-executive-officer

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.